Drug Development Consulting BidCo ApS
CVR 42287067 · Private limited company (ApS) · Active · Low risk
Drug Development Consulting BidCo ApS is a Private limited company (ApS), founded on , based in Brøndby. The company is registered in the industry virksomhedsrådgivning og anden ledelsesrådgivning. Our model estimates a bankruptcy risk of 0.6% over the next 12 months, which is 0.4 times the average for Danish companies. 5 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK 32.5m and a net result of DKK -61.3m. CEO: René Holmen Pedersen.
Bankruptcy risk for Drug Development Consulting BidCo ApS
0.4 × the average (1.41%) · higher risk than 66% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 42287067
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (5 years)
- Address
- c/o KLIFO A/S, Abildager 24
2605 Brøndby - Municipality
- Brøndby
- Industry
- Virksomhedsrådgivning og anden ledelsesrådgivning (702000)
Bankruptcies in the industry: Virksomhedsrådgivning og anden rådgivning om driftsledelse - Share capital
- DKK 40k
- Auditor
- EY Godkendt Revisionspartnerselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 0 of 5 |
| Missing annual report | No |
| Negative equity | No |
| Equity ratio | 35.3% |
| Current ratio | 5% |
| Moves (last 2 years) | 1 |
| CEO changes in total | 5 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 0 |
| Going-concern uncertainty | Yes |
Financials and key figures
| Financial year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Gross profit | DKK 5.9m | DKK 3.4m | DKK 2.3m |
| Net profit | DKK -61.3m | DKK -13.2m | DKK -9.4m |
| Equity | DKK 32.5m | DKK 79.0m | DKK 70.2m |
| Total assets | DKK 92.0m | DKK 126.0m | DKK 120.7m |
| Cash | DKK 177k | DKK 949k | – |
| Short-term debt | DKK 44.7m | DKK 47.1m | – |
| Avg. employees | 2 | 1 | – |
Latest annual report: Reporting class C, mellemstor virksomhed · auditor's statement: Independent Auditor’s Report · EY Godkendt Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 180 | ||
| 1 Jan 2024 – 31 Dec 2024 | 136 | ||
| 1 Jan 2023 – 31 Dec 2023 | 123 | ||
| 1 Jan 2022 – 31 Dec 2022 | 167 | ||
| 8 Apr 2021 – 31 Dec 2021 | 151 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | René Holmen Pedersen | Current | |
| CEO | Jasper Michiel van Gorp | ||
| CEO | Alejandra Maria Cristina Bonifacini Mørk | ||
| CEO | Rasmus Koch Nelund | ||
| Board | Redmar Koene | Current | |
| Board | Niels Peder Nielsen | Current | |
| Board | Alejandra Maria Cristina Bonifacini Mørk | Current | |
| Board | Rafael Natanek | Current | |
| Board | Mette Kirstine Agger | ||
| Board | Rafael Natanek | ||
| Owner (100%) | Drug Development Consulting Holding ApS | Current | |
| Auditor | EY Godkendt Revisionspartnerselskab | Current | |
| Founder | Drug Development Consulting Holding ApS | Current |
The CEOs' other companies
René Holmen Pedersen – 3 other companies
- Drug Development Consulting Holding ApS Active
- KLIFO A/S Active
- TFS TRIAL FORM SUPPORT ApS Active
Alejandra Maria Cristina Bonifacini Mørk – 11 other companies
- DDC Mørk Holding ApS Active
- Drug Development Consulting Holding ApS Active
- Epoqe Pharma ApS Active
- HERON HOLDING A/S Opløst
- KLIFO A/S Active
- Life Science Legal ApS Active
- Loma Therapeutics ApS Active
- Mørk Consulting ApS Active
- Phillips-Medisize A/S Active
- Scandion Oncology A/S Opløst
- TAKEDA PHARMA A/S Active
Rasmus Koch Nelund – 10 other companies, of which 2 bankrupt
- PIPELINE BIOTECH A/S Bankrupt 31 May 2016
- RR Blockchain Operations ApS Bankrupt 30 Nov 2022
- ADDICO ApS Compulsorily dissolved
- ANSN ApS Active
- CAVEO ApS Compulsorily dissolved
- Drug Development Consulting Holding ApS Active
- HERAX METHODS A/S Opløst
- KLIFO A/S Active
- Life Sciences Advisory ApS Active
- PASSION & DISCIPLINE ApS Active
Address history (2 moves)
| c/o KLIFO A/S, Abildager 24, 2605 Brøndby | |
| c/o Gorrissen Federspiel, Smedeland 36, 2600 Glostrup | |
| c/o Gorrissen Federspiel, Axeltorv 2, 1609 København V |
Similar companies in Brøndby
- ZOREEN PRAXIS ApS Brøndby
- Fortrin ApS Brøndby
- Vaisor ApS Brøndby
- JLA Advisory ApS Brøndby Strand
- ComPartner ApS Brøndby
- Logicare ApS Brøndby
- Pharma Tech ApS Brøndby
- GUAX ApS Brøndby
- Auxia Consulting ApS Brøndby
- StratPlan Advisors ApS Brøndby
- RUH solutions ApS Brøndby
- KF Tilskud ApS Brøndby
Questions and answers about Drug Development Consulting BidCo ApS
Has Drug Development Consulting BidCo ApS gone bankrupt?
No, Drug Development Consulting BidCo ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Drug Development Consulting BidCo ApS?
Our model estimates a bankruptcy risk of 0.6% over the next 12 months (low risk), which is 0.4 times the average for Danish companies.
Who is the CEO of Drug Development Consulting BidCo ApS?
René Holmen Pedersen is the CEO of Drug Development Consulting BidCo ApS.
Who is the auditor of Drug Development Consulting BidCo ApS?
Drug Development Consulting BidCo ApS most recently used EY Godkendt Revisionspartnerselskab.
When was Drug Development Consulting BidCo ApS founded?
Drug Development Consulting BidCo ApS was founded on 8 April 2021.
What is the equity of Drug Development Consulting BidCo ApS?
Equity was DKK 32.5m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.